Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.

Abstract:

INTRODUCTION:Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgically with the aromatase inhibitor anastrazole with those from MCF7 cells adapted to long-term oestrogen deprivation (LTED) (2) to assess the clinical value of selected genes in public clinical data sets and (3) to determine the impact of targeting these genes with novel agents. METHODS:Gene expression and Ki67 data were available from 69 postmenopausal women with oestrogen receptor-positive (ER+) early BC, at baseline and 2 weeks after anastrazole treatment, and from cell lines adapted to LTED. The functional consequences of target genes on proliferation, ER-mediated transcription and downstream cell signalling were assessed. RESULTS:By intersecting genes predictive of a poor change in Ki67 with those upregulated in LTED cells, we identified 32 genes strongly correlated with poor antiproliferative response that were associated with inflammation and/or immunity. In a panel of LTED cell lines, C-X-C chemokine receptor type 7 (CXCR7) and CXCR4 were upregulated compared to their wild types (wt), and CXCR7, but not CXCR4, was associated with reduced relapse-free survival in patients with ER+ BC. The CXCR4 small interfering RNA variant (siCXCR4) had no specific effect on the proliferation of wt-SUM44, wt-MCF7 and their LTED derivatives. In contrast, siCXCR7, as well as CCX733, a CXCR7 antagonist, specifically suppressed the proliferation of MCF7-LTED cells. siCXCR7 suppressed proteins associated with G1/S transition and inhibited ER transactivation in MCF7-LTED, but not wt-MCF7, by impeding association between ER and proline-, glutamic acid- and leucine-rich protein 1, an ER coactivator. CONCLUSIONS:These data highlight CXCR7 as a potential therapeutic target warranting clinical investigation in endocrine-resistant BC.

journal_name

Breast Cancer Res

authors

Ribas R,Ghazoui Z,Gao Q,Pancholi S,Rani A,Dunbier A,Dowsett M,Martin LA

doi

10.1186/s13058-014-0447-1

subject

Has Abstract

pub_date

2014-10-31 00:00:00

pages

447

issue

5

eissn

1465-5411

issn

1465-542X

pii

s13058-014-0447-1

journal_volume

16

pub_type

杂志文章
  • HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.

    abstract:BACKGROUND:Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth factor receptor 2 (HER2) expression on CTCs and tdEVs of metastatic breast cancer patients. METHODS:B...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01323-5

    authors: Nanou A,Zeune LL,Bidard FC,Pierga JY,Terstappen LWMM

    更新日期:2020-08-12 00:00:00

  • Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.

    abstract:BACKGROUND:Well-tolerated and commonly used medications are increasingly assessed for reducing breast cancer risk. These include metformin and statins, both linked to reduced hormone availability and cell proliferation or growth and sometimes prescribed concurrently. We investigated independent and joint associations o...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01336-0

    authors: Lee Argov EJ,Acheampong T,Terry MB,Rodriguez CB,Agovino M,Wei Y,Athilat S,Tehranifar P

    更新日期:2020-09-15 00:00:00

  • Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.

    abstract:BACKGROUND:The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in cases of European, African, and Latin American ancestry. METHODS:BC mutation carrier cases from...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01341-3

    authors: Tuazon AMA,Lott P,Bohórquez M,Benavides J,Ramirez C,Criollo A,Estrada-Florez A,Mateus G,Velez A,Carmona J,Olaya J,Garcia E,Polanco-Echeverry G,Stultz J,Alvarez C,Tapia T,Ashton-Prolla P,Brazilian Familial Cancer Network

    更新日期:2020-10-21 00:00:00

  • Breast cancer intra-tumor heterogeneity.

    abstract::In recent years it has become clear that cancer cells within a single tumor can display striking morphological, genetic and behavioral variability. Burgeoning genetic, epigenetic and phenomenological data support the existence of intra-tumor genetic heterogeneity in breast cancers; however, its basis is yet to be full...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3658

    authors: Martelotto LG,Ng CK,Piscuoglio S,Weigelt B,Reis-Filho JS

    更新日期:2014-05-20 00:00:00

  • Epigenetics in breast cancer: what's new?

    abstract::Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expressi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2925

    authors: Huang Y,Nayak S,Jankowitz R,Davidson NE,Oesterreich S

    更新日期:2011-01-01 00:00:00

  • Accelerated partial breast irradiation: technically feasible but who will benefit?

    abstract::Modern breast cancer radiotherapy aims to increase uncomplicated cure rates. A priority is reduction of late effects which include chronic chest wall or breast pain, poor cosmesis, and cardiac toxicity. As breast screening detects early cancers we may be able to safely restrict irradiation postlumpectomy to the tumour...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1016

    authors: Ross G

    更新日期:2005-01-01 00:00:00

  • The pathology of familial breast cancer: Morphological aspects.

    abstract::A small proportion of breast cancers are due to a heritable predisposition. Recently, two predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The morphological features of tumours from patients harbouring mutations in the BRCA1 and BRCA2 genes differ from each other and from sporadic breast cancers...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr10

    authors: Lakhani SR

    更新日期:1999-01-01 00:00:00

  • Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.

    abstract:BACKGROUND:Bone is one of the most frequent metastatic sites of advanced breast cancer. Current therapeutic agents aim to inhibit osteoclast-mediated bone resorption but only have palliative effects. During normal bone remodeling, the balance between bone resorption and osteoblast-mediated bone formation is essential f...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1059-y

    authors: Liu X,Cao M,Palomares M,Wu X,Li A,Yan W,Fong MY,Chan WC,Wang SE

    更新日期:2018-10-22 00:00:00

  • RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation.

    abstract:INTRODUCTION:In response to gamma-irradiation (IR)-induced double-strand DNA breaks, cells undergo cell-cycle arrest, allowing time for DNA repair before reentering the cell cycle. G2/M checkpoint activation involves activation of ataxia telangiectasia mutated (ATM)/ATM- and rad3-related (ATR) kinases and inhibition of...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3164

    authors: Yan Y,Greer PM,Cao PT,Kolb RH,Cowan KH

    更新日期:2012-04-11 00:00:00

  • Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.

    abstract:INTRODUCTION:Cytokeratin (CK) 14, one of several markers expressed in normal myoepithelial/basal cells, is also expressed in a proportion of breast carcinomas. Previous studies have suggested that expression of such 'basal' markers predicts different biological behaviour, with more frequent lung and brain metastases an...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1636

    authors: Fulford LG,Reis-Filho JS,Ryder K,Jones C,Gillett CE,Hanby A,Easton D,Lakhani SR

    更新日期:2007-01-01 00:00:00

  • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

    abstract:INTRODUCTION:Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2888

    authors: Fuentes G,Scaltriti M,Baselga J,Verma CS

    更新日期:2011-05-22 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract:BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-020-01349-9

    authors: O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期:2020-10-27 00:00:00

  • Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

    abstract:INTRODUCTION:Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS:Patients with four or more positive axillary nodes were identified from...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/bcr1847

    authors: Crabb SJ,Bajdik CD,Leung S,Speers CH,Kennecke H,Huntsman DG,Gelmon KA

    更新日期:2008-01-01 00:00:00

  • Chemically induced DNA hypomethylation in breast carcinoma cells detected by the amplification of intermethylated sites.

    abstract:INTRODUCTION:Compromised patterns of gene expression result in genomic instability, altered patterns of gene expression and tumour formation. Specifically, aberrant DNA hypermethylation in gene promoter regions leads to gene silencing, whereas global hypomethylation events can result in chromosomal instability and onco...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr799

    authors: Sadikovic B,Haines TR,Butcher DT,Rodenhiser DI

    更新日期:2004-01-01 00:00:00

  • DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.

    abstract:INTRODUCTION:Aberrant activation of Wnt/β-catenin signaling plays an important role in the pathogenesis of breast cancer. DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/β-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in brea...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3399

    authors: Yin X,Xiang T,Li L,Su X,Shu X,Luo X,Huang J,Yuan Y,Peng W,Oberst M,Kelly K,Ren G,Tao Q

    更新日期:2013-03-12 00:00:00

  • Alternative splicing and the progesterone receptor in breast cancer.

    abstract::Progesterone receptor status is a marker for hormone responsiveness and disease prognosis in breast cancer. Progesterone receptor negative tumours have generally been shown to have a poorer prognosis than progesterone receptor positive tumours. The observed loss of progesterone receptor could be through a range of mec...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2097

    authors: Cork DM,Lennard TW,Tyson-Capper AJ

    更新日期:2008-01-01 00:00:00

  • Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.

    abstract:INTRODUCTION:Although aberrant tyrosine kinase signalling characterises particular breast cancer subtypes, a global analysis of tyrosine phosphorylation in mouse models of breast cancer has not been undertaken to date. This may identify conserved oncogenic pathways and potential therapeutic targets. METHODS:We applied...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0437-3

    authors: Ali NA,Wu J,Hochgräfe F,Chan H,Nair R,Ye S,Zhang L,Lyons RJ,Pinese M,Lee HC,Armstrong N,Ormandy CJ,Clark SJ,Swarbrick A,Daly RJ

    更新日期:2014-09-09 00:00:00

  • Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype.

    abstract:INTRODUCTION:The tumour-suppressive effects of transforming growth factor-beta (TGF-beta) are well documented; however, the mechanistic basis of these effects is not fully understood. Previously, we showed that a non-canonical member of the Wingless-related protein family, Wnt5a, is required for TGF-beta-mediated effec...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2244

    authors: Roarty K,Baxley SE,Crowley MR,Frost AR,Serra R

    更新日期:2009-01-01 00:00:00

  • Dendritic cell defects in patients with cancer: mechanisms and significance.

    abstract::Dendritic cells (DCs) are a complex network of antigen-presenting cells that have an essential role in the modulation of primary immunity. There has been increasing evidence that DCs isolated from patients with malignancy demonstrate functional deficiencies that inhibit the capacity to mount an effective anti-tumor re...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/bcr1375

    authors: Lenahan C,Avigan D

    更新日期:2006-01-01 00:00:00

  • Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

    abstract:INTRODUCTION:The invasive, mesenchymal phenotype of CD44posCD24neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44neg/lowCD24pos breast cancer cells lack the ability to give rise to their invasive CD44posCD24ne...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2449

    authors: Meyer MJ,Fleming JM,Ali MA,Pesesky MW,Ginsburg E,Vonderhaar BK

    更新日期:2009-01-01 00:00:00

  • HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.

    abstract:INTRODUCTION:Classification of breast cancers according to the HER-2 oncogene status is of central importance in the selection of post-surgical therapies. A decrease in the proportion of HER-2-positive breast cancer has been suspected, but no data on the incidence trends at population level have been reported. METHODS...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2322

    authors: Köninki K,Tanner M,Auvinen A,Isola J

    更新日期:2009-01-01 00:00:00

  • Trastuzumab emtansine: mechanisms of action and drug resistance.

    abstract::Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3621

    authors: Barok M,Joensuu H,Isola J

    更新日期:2014-03-05 00:00:00

  • Functional variants at the 21q22.3 locus involved in breast cancer progression identified by screening of genome-wide estrogen response elements.

    abstract:INTRODUCTION:Estrogen forms a complex with the estrogen receptor (ER) that binds to estrogen response elements (EREs) in the regulatory region of estrogen-responsive genes and regulates their transcription. Sequence variants in the regulatory regions have the potential to affect the transcription factor-regulatory sequ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0455-1

    authors: Hsiung CN,Chu HW,Huang YL,Chou WC,Hu LY,Hsu HM,Wu PE,Hou MF,Yu JC,Shen CY

    更新日期:2014-10-09 00:00:00

  • Finding the needle in the haystack: why high-throughput screening is good for your health.

    abstract::High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to exploit, for maximum therapeutic benefit, the large number of new molecular targets emerging from the Human G...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr440

    authors: Aherne GW,McDonald E,Workman P

    更新日期:2002-01-01 00:00:00

  • The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

    abstract:INTRODUCTION:Breast cancers can be classified using whole genome expression into distinct subtypes that show differences in prognosis. One of these groups, the basal-like subtype, is poorly differentiated, highly metastatic, genomically unstable, and contains specific genetic alterations such as the loss of tumour prot...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2142

    authors: Herschkowitz JI,He X,Fan C,Perou CM

    更新日期:2008-01-01 00:00:00

  • Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

    abstract:BACKGROUND:The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s13058-017-0883-9

    authors: Toomey S,Eustace AJ,Fay J,Sheehan KM,Carr A,Milewska M,Madden SF,Teiserskiene A,Kay EW,O'Donovan N,Gallagher W,Grogan L,Breathnach O,Walshe J,Kelly C,Moulton B,Kennedy MJ,Gullo G,Hill AD,Power C,Duke D,Hambly N

    更新日期:2017-07-27 00:00:00

  • Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

    abstract:INTRODUCTION:The re-emergence of the tumour growth factor-beta (TGF-beta)-related embryonic morphogen Nodal has recently been reported in several different human cancers. In this study, we examined the expression of Nodal in a series of benign and malignant human breast tissues to determine the clinical significance of...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3185

    authors: Strizzi L,Hardy KM,Margaryan NV,Hillman DW,Seftor EA,Chen B,Geiger XJ,Thompson EA,Lingle WL,Andorfer CA,Perez EA,Hendrix MJ

    更新日期:2012-05-11 00:00:00

  • Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.

    abstract:INTRODUCTION:The aim of this study was to describe breast tumor subtypes by common breast cancer risk factors and to determine correlates of subtypes using baseline data from two pooled prospective breast cancer studies within a large health maintenance organization. METHODS:Tumor data on 2544 invasive breast cancer c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2261

    authors: Kwan ML,Kushi LH,Weltzien E,Maring B,Kutner SE,Fulton RS,Lee MM,Ambrosone CB,Caan BJ

    更新日期:2009-01-01 00:00:00

  • Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

    abstract:INTRODUCTION:Breast tumor kinase (Brk/protein tyrosine kinase 6 (PTK6)) is a nonreceptor, soluble tyrosine kinase overexpressed in the majority of breast tumors. Previous work has placed Brk downstream of epidermal growth factor receptor (ErbB) activation and upstream of extracellular signal-regulated kinase 5 (ERK5) a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2622

    authors: Castro NE,Lange CA

    更新日期:2010-01-01 00:00:00

  • The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

    abstract:INTRODUCTION:Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2598

    authors: Ikeda H,Taira N,Hara F,Fujita T,Yamamoto H,Soh J,Toyooka S,Nogami T,Shien T,Doihara H,Miyoshi S

    更新日期:2010-01-01 00:00:00